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Department of Rheumatology, Nether Edge Hospital, Sheffield Sulphasalazine is now recognised to be a useful agent in the management of rheumatoid arthritis (Bax & Amos 1985; McConkey et al. 1980; Neumann et al. 1983; Pullar et al. 1983) . After ingestion it reaches the colon unchanged; here colonic bacteria cleave the azo bond, releasing sulphapyridine and 5-acetylsalicylic acid. The sulpha· pyridine is well absorbed and there is evidence to suggest it may be the active moiety (Pullar et al. 1985) . A major pathway in the metabolism of sulphapyridine involves the process of acetylation, and the rate of acetylation is genetically determined.
The clinical response to sulphasalazine in rheumatoid arthritis is unpredictable (Bax & Amos 1985) ; some patients do very well, but others derive little obvious benefit. Working from the hypothesis that these differences may relate to differences in metabolism or differences in drug dose requirements, we have sought to establish a relationship between treatment outcome, acetylator phenotype and drug dose per unit of bodyweight. The results of the study are reported more fully elsewhere (Bax et al. in press ).
We found among 79 patients investigated that there was a trend for slow acetylators to be overrepresented among very good responders, and th\s trend was just significant (p < 0.05). However, any i Enteric-coated sulphasaiazine was used in this study; marketed by Pharmacia Ltd as Salazopyrin® EN-tabs, Azulfidine® EN-tabs® (USA), Azulfidine RA ® (Germany).
relationship between outcome and acetylator phenotype is too weak to make it worth routinely assessing acetylator phenotype before treatment.
Drug dosage per unit of bodyweight had no predictive value for treatment outcome, being the same for good and poor responders. Our standard regimen is to aim for 2g daily of enteric-coated sulphasalazine, and we find that higher doses frequently cause more toxicity with few extra therapeutic benefits, whatever the weight of the patient.
